Trials / Completed
CompletedNCT00520390
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)
A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38) Administered Weekly for 3 Weeks in 4-Week Cycles in Patients With Advanced Solid Tumors or Ymphoma (EZN-2208-02)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (planned)
- Sponsor
- Enzon Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to patients with advanced cancer or lymphoma. The safety of the study drug and its effect on the disease will also be studied. Enzon will also perform pharmacokinetic (PK) testing of EZN-2208. PK testing measures the amount of a drug in the body at different time points.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EZN-2208 |
Timeline
- Start date
- 2007-05-01
- First posted
- 2007-08-24
- Last updated
- 2010-04-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00520390. Inclusion in this directory is not an endorsement.